Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Due to a high percentage of hemoglobin F, Hemoglobin A1C (HbA1C) measurements are inaccurate for assessing glycemia in infants. We aimed to determine when HbA1C might have utility and to assess the value of fructosamine. We measured HbA1C in healthy infants aged 3 weeks to 12 months. Hemoglobin, HbA1C, hemoglobin electrophoresis, fructosamine, and albumin levels were collected. Mean age was 193.9 ± 94.5 days; participants were 60.9% male, 80.4% white, and 15.2% Hispanic. Mean HbA1C (n=31) and fructosamine (n=33) were 5.0% (31 mmol/mol) (range 4.4-5.9%; 25-41 mmol/mol) and 217 (range 186-261 mCmol/L), respectively. HbA1C percentages negatively correlated with HbF percentages (p < 0.005) and rose with increasing age in infants <6 months (p < 0.01). Fructosamine did not vary with age. Normalizing HbA1C to hemoglobin fractions or fructosamine to albumin did not change significance. We conclude that HbA1C values (via HPLC) likely become a reliable marker of glycemia after 6 months of age and that fructosamine may be a better measure during this young age.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083632 | PMC |
| http://dx.doi.org/10.1101/2025.05.07.25327198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of transitioning from conventional blood glucose monitoring to continuous glucose monitoring on glycemic control and self-management in adults with type 2 diabetes on oral glucose-lowering medications.
Diabetes Res Clin Pract
September 2025
Health Education Department, and Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background: Despite advances, glycemic control in people with type 2 diabetes (PwT2D) treated with oral antidiabetic medications (ADMs) often remains suboptimal. Continuous glucose monitoring (CGM) has shown promise in diabetes management, offering real-time insights into glucose trends. This study evaluates the impact of transitioning from conventional self-monitoring of blood glucose (SMBG) to CGM on glycemic outcomes and self-management in PwT2D receiving oral ADMs.
View Article and Find Full Text PDFNomogram models for predicting sarcopenia in elderly Asian patients with type 2 diabetes.
Clinics (Sao Paulo)
September 2025
Ultrasound Department, Jinan People's Hospital, Laiwu District, Jinan City, Shandong Province, China.
Background: Sarcopenia is a prevalent but underrecognized complication in elderly patients with Type 2 Diabetes Mellitus (T2DM). Its complex etiology limits early diagnosis and intervention. This study developed and internally validated a nomogram for individualized sarcopenia risk assessment in this population.
View Article and Find Full Text PDFCurrent status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.
Drug Deliv Transl Res
September 2025
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.
Diabetes is a metabolic disorder of increasing global concern. Characterized by constantly elevated levels of glucose, severe β-cell dysfunction, and insulin resistance, it is the cause of a major burden on patients if not managed with therapeutic and lifestyle changes. The human body is slowly developing tolerance to many marketed antidiabetic drugs and the quest for the discovery of newer molecules continues.
View Article and Find Full Text PDFAssociation between haemoglobin levels and the risk of diabetic retinopathy in adults with type 2 diabetes: a retrospective cohort study using the TriNetX network.
Eye (Lond)
September 2025
Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan city, Taiwan.
Background: Diabetic retinopathy (DR) is the leading cause of preventable blindness. Although hyperglycaemia is the primary driver, other modifiable risk factors may contribute to DR development. This study investigated the association between haemoglobin levels and DR risk in adults with type 2 diabetes.
View Article and Find Full Text PDFPredicting stimulated C-peptide in type 1 diabetes using machine learning: a web-based tool from the T1D exchange registry.
Diabetes Res Clin Pract
September 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey.
Aims: The mixed-meal tolerance test (MMTT), though considered the gold standard for evaluating residual beta-cell function in type 1 diabetes mellitus (T1D), is impractical for routine use. We aimed to develop and validate a machine learning (ML) model to predict MMTT-stimulated C-peptide categories using routine clinical data.
Methods: Data from 319 individuals in the T1D Exchange Registry with complete MMTT and clinical information were analyzed.